1Huxtable LM,Tafreshi MJ,Rakkar AN.Fregquency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists[J].Am J Cardiol,2006,97:426-429.
3Ahmed I, Majeed A, Powell R. Heparin induced thrombocyto- penia : diagnosis and management update. Postgrad Med J, 2007, 83(983) : 575-582.
4Abrams CS, Cines DB. Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors. Curt Hematol Rep, 2004, 3(2): 143-147.
5Bougie DW, Wilker PR, Wuitschick ED, et al. Acute throm- bocytopenia after treatment with tirofiban or eptifibatide is associa- ted with antibodies specific for ligand-occupied GPIIb/IIIa. Blood, 2002, 100(6) : 2071-2076 .
6Said SM, Hahn J, Schleyer E, et al. Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia: diagnosis and treatment. Clin Res Cardiol, 2007, 96(2) : 61-69.
7Aster RH, Curtis BR, Bougie DW, et al. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors : position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J Thromb Haemost, 2006, 4(3) : 678-679.
8Billheimer JT, Dicker IB, Wyrm R, et al. Evidence that throm- bocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood, 2002, 99(10): 3540-3546.
